EIF3A and acute lymphoblastic leukemia: To test whether these cells retained sensitivity to venetoclax, the leukemic cells isolated from recipients (both vehicle and ventoclax-treated) were treated in culture with venetoclax and compared them to the parental human BCL-2 p185+ B-ALL re-programmed cells.